Results point to potential of Ashvattha’s migaldendranib

Privately-held Ashvattha Therapeutics, a Californian firm advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in regions of inflammation, has announced positive Phase II data for migaldendranib, a novel subcutaneously (subQ) administered nanomedicine treatment for retinal diseases.

SubQ-administered MGB selectively targets and reduces fluid production in the retina of both eyes to reduce the need for therapies that remove the fluid after an injection in the eye. 

These promising results highlight our dedication to developing innovative therapies for wet AMD and DME